【藥品訊息】 猛健樂筆 5 mg/0.6 mL 中文仿單 猛健樂筆 5 mg/0.6 mL 衛教單張

An adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus.

Tirzepatide is a GIP and a GLP-1 receptor agonist. It is an amino acid sequence with a C20-fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide enhances first- and second-phase insulin secretion, and reduces plasma glucagon levels, both in a glucose-dependent manner.

Protein binding: 99% to plasma albumin.
Bioavailability: 80%.
Half-life elimination: ~5 days.
Time to peak: 8 to 72 hours.
Excretion: Urine and feces (as metabolites).

Serious hypersensitivity to tirzepatide or any component of the formulation.

Contraindication

Contraindication

Constipation, decreased appetite, diarrhea, nausea, vomiting

SUBQ
Initial: 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. May increase dose in 2.5 mg/week increments every 4 weeks if needed to achieve glycemic goals (maximum weekly dose: 15 mg/week).
Note: The lower initial dose (2.5 mg weekly) is intended to reduce GI symptoms; it does not provide effective glycemic control. If changing the day of administration is necessary, allow at least 72 hours between 2 doses.

Use in pediatric patients (<18 years of age) is not indicated.

No dosage adjustment necessary.

No dosage adjustment necessary.